Lonza has promoted Stefan Troger to site manager of its plant in Visp, Switzerland. He takes up the role next April and will report to Harry Boot. With this appointment, leadership of the site and the Visp Challenge project will be merged into one.
Troger will succeed Stéphane Mischler, who after a long and impressive career spanning more than 30 years, is retiring. He will support Troger and the site management team until his retirement date and will also continue to work with Lonza’s pension fund.
Troger has held several positions within Lonza over the past 19 years. Most recently he was head of Biopharma Manufacturing in Visp and took over the leadership of the Visp Challenge project, which maps out the future set-up of the Visp site.
‘With Stefan Troger we have the possibility to unify the site leadership of the Visp site and project management of Visp Challenge,’ commented Stefan Borgas, chief executive of Lonza.
‘Our Visp site is confronted with major challenges in regards to currency, markets and technologies. The Visp Challenge project is working on two ends: increase productivity (lower cost and higher output from existing plants) in the short- and mid-term and improve the product portfolio to secure the future of Visp in the long-term.
‘Stefan Troger and his team have the right skill sets and the necessary level of positive energy to make this happen.’
Lonza promotes Stefan Troger to Visp site manager
He succeeds Stéphane Mischler, who retires next year
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Research & Development
The IND advantage: why early derisking is a strategic imperative for complex biologics
As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Research & Development
Stipple Bio enters into multi-target license agreement with Lonza to advance precision oncology ADC therapies
Stipple Bio’s Pointillist Platform identifies tumour-specific cell surface epitopes that, when combined with Lonza’s clinically validated ADC platform, may enable first-in-class and best-in-class ADC oncology medicines such as STP-100
Research & Development
Lonza advances integrated DNA‑to‑IND programmes with acceleration, derisking and innovation
New GS Ori‑Go vector technology supports titers higher than 11 g/L and reliable bulk pool stability, enabling more predictable material generation and shortened cell line development timelines
Manufacturing
Lonza expands AAV offering with Xcite AAV stable Producer Cell Line platform to idustrialise Viral Vector Manufacturing
New technology demonstrates superior performance versus transient transfection in clinically relevant customer gene of interest and engineered capsid, enabling scalable and cost-effective AAV manufacturing. Launch reflects Lonza’s deep expertise in cell line development, viral vector manufacturing, and platform industrialisation built over decades of supporting complex biologics
Manufacturing
Lonza delivers strong performance in Q1 2026 in line with expectations and confirms full-year Outlook 2026
Basel, Switzerland, 8 May 2026 – In its qualitative Q1 2026 business update, Lonza1 reported a strong performance across its CDMO business in line with the expected trajectory for Full-Year 2026. As expected, due to a lower prior year base, campaign timing and product releases, and planned site shutdowns, CER sales growth and CORE EBITDA margin will be notably stronger in the first half of 2026 than in the second half